Life sciences briefing: Wednesday, Jan. 23, 2008
TODAY’S HEADLINES:
Mauna Kea Tech raises $30M for in-vivo cellular imaging (release)
Knopp Neuro takes in $10M for Lou Gehrig’s drug (release)
Cardiovascular Systems, arterial-plaque device maker, files for $86M IPO (Edgar)
Diagnostics maker BG Medicine withdraws IPO (release)
Signature Genomics Labs sells stake to Ampersand Ventures (release)
Cambridge Temp raises £375K for new ovulation detector (release)
Mauna Kea Tech raises $30M for in-vivo cellular imaging — Mauna Kea Technologies, a Paris, France, developer of cellular-imaging technology, raised $30 million in a… Continue Reading
Life sciences briefing: Thursday, Dec. 6, 2007
(UPDATED: Expanded items on LineaGen, BG Medicine. Pelikan Tech is described in a standalone item here.)
TODAY’S HEADLINES:
Pelikan Tech raises $69M for diabetes glucose tests (release)
Utah’s LineaGen draws $6M for genetic diagnostics (VentureWire, sub req’d)
Beijing’s IKang Healthcare gets $25M for medical-service centers (VW)
BG Medicine drops IPO price range, seeks up to $52M (Edgar)
Sepragen completes acquisition of Cyto Biologic Tech (release)
Utah’s LineaGen draws $6M for genetic diagnostics — LineaGen (no Web site), a Salt Lake City biotech focused… Continue Reading
IPO roundup: Broncus Tech aims to breathe in $86M, Aegerion Pharma rides again, and more
Broncus Tech, medical device maker, files for $86M IPO — Broncus Technologies, a Mountain View, Calif., developer of minimally invasive devices for treating emphysema, filed to raise $86 million in an initial offering. The company’s SEC filing is here.
The Broncus technology is a minimally invasive, catheter-based device that creates new passages to bypass collapsed airways in the lungs caused by chronic smoking and similar issues, enabling trapped air to escape. Broncus is only one of… Continue Reading
Life sciences briefing: Monday, Oct. 8, 2007
Featured companies: AirInSpace, Anacor Pharmaceuticals, Apollo Endosurgery, Ascension Health Partners, BG Medicine, CeraPedics, GlaxoSmithKline, Simplex Diabetic Supply, Zars Pharma
UPDATED: Last entry added at 2am PT on 10/8/07.
Anacor Pharma pulls in $22M from Glaxo, with hundreds of millions more on the line –Palo Alto, Calif.-based Anacor Pharmaceuticals, a biotech developing new anti-infective and anti-inflammatory drugs using boron chemistry, struck a wide-ranging partnership with GlaxoSmithKline worth up to $605 million. Anacor will receive a $12 million cash payment and… Continue Reading
Life sciences briefing: Monday, Aug. 6, 2007
(UPDATED at 5:05 p.m. PDT; see below.)
(As part of my ongoing effort to strike the right balance between keeping up with venture-business news and writing more analysis, I’m inaugurating a daily briefing that will collect deal-related news items from the life sciences in one place. I’ll continue updating this post throughout the day as the news dictates. Comments on this or any other feature of this blog are always welcome; sound off below. For more on… Continue Reading